TMS Research: What the Published Literature Shows
A plain-language look at real, peer-reviewed studies on TMS for depression — summarized
honestly, cited fully, and framed around what general research can and can’t tell you about your
own situation.
At DTIP, TMS is delivered on the MagVenture TMS Therapy System (MagPro stimulator with
Cool-B65/Cool-B70 coils), FDA-cleared for the treatment of depressive episodes, and decreasing
anxiety symptoms in patients with comorbid anxiety, in adults with Major Depressive Disorder who
failed to improve on prior antidepressant treatment.
Keep that exact scope in mind as you read the studies below. TMS as a modality has been
FDA-cleared for depression since 2008, and the broader research literature on TMS covers many
devices, protocols, and patient populations — not only the specific device and protocol used
at DTIP. We’ve noted where a cited study relates to a different device, protocol, or condition than
DTIP’s on-label use, so you can read each finding in its proper context.
How to read what’s below
The three studies summarized on this page are real, published, peer-reviewed sources on TMS
(transcranial magnetic stimulation, sometimes written as rTMS for “repetitive TMS”) and depression.
Each entry includes a plain-language summary of what the study actually found, a note on the type
and quality of evidence it represents, and a full citation with a link to the original source so you
can read it yourself.
This is general scientific literature about TMS as a treatment approach — it is not a promise
about what will happen for any individual person, including you. Study populations, protocols, and
outcome measures vary, and results vary from person to person. A DTIP provider will talk through
what’s realistic for your specific history and symptoms during a real clinical evaluation.
The published research
Comparing accelerated and standard rTMS protocols for depression
This 2025 systematic review pulled together 23 articles examining “accelerated” rTMS schedules
— protocols that deliver multiple stimulation sessions per day over a shorter overall
calendar period — compared against standard once-daily rTMS schedules and sham (inactive)
stimulation, in the treatment of depression, including treatment-resistant depression. Rather than
simply asking whether rTMS works, the review focused on protocol-level variables — things
like session frequency, spacing between sessions, and total stimulation dose — that can
influence how a course of treatment performs.
near the top of the evidence hierarchy because they synthesize findings across multiple individual
studies rather than reporting results from a single trial, though the strength of any systematic
review still depends on the quality of the studies it includes.
According to PubMed: Lefaucheur JP, Colzi C, Hollander E, et al. “Comparison between accelerated
and standard or sham rTMS in the treatment of depression: A systematic review.” Neurosci Biobehav
Rev. 2025;173:106140.
DOI: 10.1016/j.neubiorev.2025.106140
rTMS for generalized anxiety and panic disorders
rTMS is FDA-approved for Major Depressive Disorder and for obsessive-compulsive disorder (OCD).
This 2022 systematic review and meta-analysis looked beyond those approved uses to ask what the
research literature shows about rTMS specifically for generalized anxiety disorder (GAD) and panic
disorder. Pooling results across the included studies, the researchers found statistically
significant improvement in both anxiety and depression symptom scores among GAD patients, and that
this pattern of improvement held regardless of whether patients also had other co-occurring
conditions.
combines results from multiple studies to estimate an overall effect — generally considered
strong evidence when the underlying studies are consistent, though pooled results can still be
shaped by differences in the individual trials included.
Context: This study concerns rTMS for anxiety disorders as a primary diagnosis,
not DTIP’s specific FDA-cleared use — decreasing anxiety symptoms that occur alongside a
depressive episode in adults with MDD. It’s included here as part of the broader TMS-and-anxiety
research picture, not as a description of DTIP’s protocol.
According to PubMed: Cox J, Thakur B, Alvarado L, Shokar N, Thompson PM, Dwivedi AK. “Repetitive
transcranial magnetic stimulation for generalized anxiety and panic disorders: A systematic review
and meta-analysis.” Ann Clin Psychiatry. 2022;34(2):e2-e24.
DOI: 10.12788/acp.0050
Clinical rTMS outcomes for veterans with Major Depressive Disorder
This 2017 study looked at outcomes for a group of veterans who received clinical rTMS for Major
Depressive Disorder in a real-world treatment setting, rather than a controlled research trial.
The researchers reported that about 45% of patients experienced a treatment response and about 20%
achieved remission, based on one of the outcome scales used in the study. Treatment was described
as well tolerated, and no seizures were observed in this patient cohort.
randomized, sham-controlled trial. This kind of study is valuable for showing how a treatment
performs in everyday clinical practice, but because it doesn’t include a comparison sham group,
it carries less weight as proof of cause-and-effect than a randomized controlled trial or
systematic review would.
According to PubMed: Kozel FA, Hernandez M, Van Trees K, et al. “Clinical repetitive transcranial
magnetic stimulation for veterans with major depressive disorder.” Ann Clin Psychiatry.
2017;29(4):242-248.
What This Research Does — and Doesn’t — Tell You
The studies above are examples of the general scientific literature on TMS for depression and
related conditions. They describe what researchers observed in specific study populations, using
specific protocols and outcome measures — they are not a prediction, promise, or guarantee
of what will happen for you individually.
Results vary from person to person. Your history, current symptoms, prior treatments, and overall
health all factor into what’s realistic for your care. A DTIP provider will review your specific
situation during a psychiatric evaluation and talk through what you can reasonably expect —
that conversation, not a research summary, is the right place to set expectations for your own
treatment.
Want to talk through what this means for you?
A conversation with a DTIP provider isn’t a commitment to treatment — it’s a chance to ask
questions about the research and find out honestly where you stand.